SYSTEMATIC REVIEW article
Front. Oncol.
Sec. Breast Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1556978
This article is part of the Research TopicLiquid Biopsy and Circulating Tumor DNA Assays in the Management of Breast CancerView all articles
Efficacy and safety of PI3K inhibitors combined with fulvestrant for HR+/HER2-advanced breast cancer: a systematic review and metaanalysis
Provisionally accepted
- 1Day Surgery Care Unit, Shenzhen Nanshan People's Hospital, Shenzhen, Guangdong Province, China
- 2Department of Breast and Thyroid Surgery, Shenzhen Nanshan People's Hospital, Shenzhen, Guangdong Province, China
- 3Department of Radiation Oncology, Shenzhen Nanshan People's Hospital, Shenzhen, Guangdong Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objectives：This systematic review and meta-analysis aimed to evaluate the efficacy and safety of combination of Phosphatidylinositol 3-kinase (PI3K) inhibitors and fulvestrant in patients with advanced breast cancer (ABC) who are hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-).Methods：A systematic search was conducted across the PubMed, Cochrane Library, EMBASE databases and major conference websites (ASCO, ESMO, SABCS) to identify randomized controlled trials (RCTs) evaluating the combination of PI3K inhibitors and fulvestrant in the treatment of advanced breast cancer. Two independent reviewers systematically screened the literature, extracted data, and assessed the risk of bias for the included studies based on predefined criteria. Meta-analysis was subsequently performed using R software in accordance with the PRISMA guidelines.Results：A total of five randomized controlled trials (RCTs) involving 3,011 patients were included. The findings indicated that the combination of PI3K inhibitors and fulvestrant significantly improved progression-free survival(PFS) (HR = 0.74, 95% CI 0.67-0.80, P < 0.0001) and the objective response rate (ORR) (RR = 1.80, 95% CI: 1.39-2.35, P < 0.0001) compared to placebo plus fulvestrant. However, there was no statistically significant difference in clinical benefit rate (CBR) (RR = 1.10, 95% CI: 0.97-1.25, P = 0.1341). Subgroup analysis indicated that the predefined subgroup of PFS based on PIK3CA mutation status assessed by ctDNA was statistically significant (P = 0.0039), whereas the predefined subgroup of PFS based on PIK3CA mutation status assessed by tumor tissue was not statistically significant (P = 0.1514). In terms of adverse events, the incidence of grade ≥3 events was significantly increased in the PI3K inhibitors combined with fulvestrant group (RR=2.11, 95% CI: 1.73-2.58, P<0.0001), particularly hyperglycemia, rash, and transaminitis (ALT).Conclusion：The combination of PI3K inhibitors and fulvestrant significantly improved PFS and ORR in patients with advanced breast cancer. However, substantial dose-limiting toxicities associated with this therapeutic regimen restrict its broader clinical application. In patients with PIK3CA mutations detected on ctDNA analysis, PFS was significantly improved compared to those with wild-type PIK3CA, suggesting that ctDNA-based PIK3CA mutation status may serve as a potential biomarker for treatment response.
Keywords: PI3K inhibitors, Advanced breast cancer, Progression-free survival, PIK3CA mutations, Meta-analysis
Received: 07 Jan 2025; Accepted: 19 May 2025.
Copyright: © 2025 Li, Wang, Lin and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Tianwen Chen, Department of Breast and Thyroid Surgery, Shenzhen Nanshan People's Hospital, Shenzhen, Guangdong Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.